IRC 003 - Combination Therapy Study
Brief Study Description: IRC 003 is a study currently enrolling people at risk of developing complications or severe cases of influenza. The purpose of the study is to evaluate whether combination therapy (combination of three antiviral drugs - amantadine, ribavirin, oseltamivir) will help symptoms resolve faster and with fewer complications than with oseltamivir alone. Individuals who are seen at hospitals or clinics with an influenza-like illness will be screened for the study and, if eligible, will be randomized to receive either the combination therapy or oseltamivir alone for the treatment of flu.
Additional information about this trial can be found on the ClinicalTrials.gov website, under the title: Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications